Elsevier

Clinical Lung Cancer

Volume 14, Issue 5, September 2013, Pages 467-472
Clinical Lung Cancer

Review
Molecularly Targeted Therapies in Locally Advanced Non–Small-Cell Lung Cancer

https://doi.org/10.1016/j.cllc.2013.03.005Get rights and content

Abstract

Approximately a third of the patients with non-small cell lung cancer (NSCLC) present with locally advanced disease not amenable to curative resection. Concurrent chemoradiation is currently the treatment of choice for these patients. Outcomes in patients with locally advanced NSCLC treated with concurrent chemoradiation are modest at best. No significant progress has been made over the past decade in this subset of patients with NSCLC. Several trials have examined the role of molecular targeted therapies in this setting. We review the results of these trials and present the outline of a proposed prospective clinical trial to evaluate targeted drugs in molecularly selected group of patients with locally advanced NSCLC.

Introduction

Lung cancer is the leading cause of cancer-related mortality, with an estimated 160,340 deaths in the United States for the year 2012.1 Approximately 85% of patients with lung cancer have the non–small-cell lung cancer (NSCLC) subtype.2 Among patients with NSCLC, approximately 25%-30% present with locally advanced non–small-cell cancer, for which concurrent chemotherapy and radiation offer the best potential for cure.3, 4 Even though concurrent chemoradiation significantly improves outcomes in this patient cohort compared with radiation alone or sequential chemoradiation, most of the patients eventually relapse at a distant site. We appear to have reached a plateau in terms of efficacy with currently available cytotoxic chemotherapy regimens that are used in conjunction with thoracic radiation. There is an urgent need to develop novel therapies to improve the outcomes of patients with locally advanced lung cancer.

Over the past decade, several targeted agents have received approval for the management of a wide variety of cancers. Agents that target the epidermal growth factor receptor (EGFR), angiogenesis (vascular endothelial growth factor [VEGF] pathway), and the echinoderm microtubule–associated-like 4-anaplastic lymphoma kinase (EML4-ALK) fusion gene are currently approved for the management of metastatic lung cancer. The efficacy these agents have demonstrated in advanced stage disease led to the design of several trials investigating their role in the management of locally advanced disease.5, 6, 7 We will review the results of clinical trials involving molecularly targeted agents in the treatment of locally advanced NSCLC.

Section snippets

Epidermal Growth Factor Receptor Inhibitors

It is estimated that nearly 16% of advanced stage nonsquamous lung carcinomas carry EGFR gene mutations.8 Mutations in EGFR often result in the constitutive activation of several downstream signaling pathways leading to cellular proliferation. Specific mutations in the EGFR tyrosine kinase (TK) domain have been associated with responses to EGFR TK inhibitors such as gefitinib or erlotinib.9 Preclinical studies have shown that the EGFR pathway is activated in tumors after radiation.10, 11, 12

Cetuximab

It is hypothesized that monoclonal antibodies such as cetuximab, nimotuzumab, and panitumumab bind with the extracellular portion of the EGFR and inhibit pathway activation by blocking receptor dimerization.15 The efficacy of combining these molecules with radiation therapy for the management of locally advanced NSCLC is being actively investigated. In the NEAR (NSCLC Erbitux and Radiotherapy) trial, 30 patients deemed “unfit” or unwilling to receive concurrent chemoradiation were treated with

Gefitinib

Initial phase I studies showed gefitinib to be well tolerated when coadministered with radiation and/or chemotherapy. In a phase I trial with 9 patients carried out by Okamoto and colleagues, pulmonary toxicity resulting in discontinuation of therapy was reported in 2 patients when gefitinib was administered concurrently with 60 Gy of radiation.29 Although the median overall survival for the study was less than a year, 2 patients whose tumor cells harbored EGFR exon 19 deletions had an overall

Bevacizumab

Bevacizumab is a monoclonal antibody that blocks circulating VEGF. Patients with both squamous (n = 12) and nonsquamous cell (n = 33) NSCLC were treated with induction therapy with paclitaxel, carboplatin, and bevacizumab in a phase I/II study by Socinski and colleagues.39 Concurrent chemotherapy with thoracic radiation was administered along with bevacizumab or bevacizumab and erlotinib. In addition, patients received consolidation therapy with bevacizumab and erlotinib. The squamous cell

Conclusions

The outcomes for patients with locally advanced NSCLC remain suboptimal with a high recurrence rate.47 The fact that many relapses occur in distant sites suggest that further progress can only be made in this subset of patients by controlling systemic disease more effectively. The results we have seen so far with the use of molecularly targeted therapies in this setting have been rather disappointing. Unfortunately, these studies have been conducted in a molecularly unselected group of

Disclosure

The authors have stated that they have no conflicts of interest.

References (47)

  • B. Center et al.

    A phase I study of gefitinib with concurrent dose-escalated weekly docetaxel and conformal three-dimensional thoracic radiation followed by consolidative docetaxel and maintenance gefitinib for patients with stage III non-small cell lung cancer

    J Thorac Oncol

    (2010)
  • S. Rothschild et al.

    Gefitinib in combination with irradiation with or without cisplatin in patients with inoperable stage III non-small cell lung cancer: a phase I trial

    Int J Radiat Oncol Biol Phys

    (2011)
  • S. Niho et al.

    Induction chemotherapy followed by gefitinib and concurrent thoracic radiotherapy for unresectable locally advanced adenocarcinoma of the lung: a multicenter feasibility study (JCOG 0402)

    Ann Oncol

    (2012)
  • T.E. Stinchcombe et al.

    Induction chemotherapy with carboplatin, irinotecan, and paclitaxel followed by high dose three-dimension conformal thoracic radiotherapy (74 Gy) with concurrent carboplatin, paclitaxel, and gefitinib in unresectable stage IIIA and stage IIIB non-small cell lung cancer

    J Thorac Oncol

    (2008)
  • N. Ready et al.

    Chemoradiotherapy and gefitinib in stage III non-small cell lung cancer with epidermal growth factor receptor and KRAS mutation analysis: cancer and leukemia group B (CALEB) 30106, a CALGB-stratified phase II trial

    J Thorac Oncol

    (2010)
  • N.W. Choong et al.

    Phase I trial of erlotinib-based multimodality therapy for inoperable stage III non-small cell lung cancer

    J Thorac Oncol

    (2008)
  • Y. Nishimura et al.

    Phase I/II trial of sequential chemoradiotherapy using a novel hypoxic cell radiosensitizer, doranidazole (PR-350), in patients with locally advanced non-small-cell lung cancer (WJTOG-0002)

    Int J Radiat Oncol Biol Phys

    (2007)
  • R. Siegel et al.

    Cancer statistics, 2012

    CA Cancer J Clin

    (2012)
  • R. Govindan et al.

    Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database

    J Clin Oncol

    (2006)
  • A.W. Blackstock et al.

    Definitive chemoradiation for the treatment of locally advanced non small-cell lung cancer

    J Clin Oncol

    (2007)
  • F.A. Shepherd et al.

    Erlotinib in previously treated non-small-cell lung cancer

    N Engl J Med

    (2005)
  • E.L. Kwak et al.

    Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer

    N Engl J Med

    (2010)
  • R. Rosell et al.

    Screening for epidermal growth factor receptor mutations in lung cancer

    N Engl J Med

    (2009)
  • Cited by (9)

    • Polymers and inorganic nanoparticles: A winning combination towards assembled nanostructures for cancer imaging and therapy

      2021, Nano Today
      Citation Excerpt :

      The pH-dependent switch of photodynamic properties of SPNs amplifies phototherapy in the acidic microenvironment of tumor while minimizing the potential side effect to normal tissues. Systemic drug delivery often fails to deliver exact dose of therapeutic agents specifically to tumor sites at the right time to suppress cancer growth and metastases [232,233]. Severe side effect arises from the non-specificity and toxicity of drugs, which can make the patient extremely weak and even result in death.

    • Targeted therapy in nonsmall cell lung cancer

      2017, Indian Journal of Cancer
    • Multimodality therapy for NSCLC

      2016, Cancer Treatment and Research
    View all citing articles on Scopus
    View full text